LKLaura Kuehlewein

Laura Kuehlewein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laura Kuehlewein has a total of 155 co-authors. Here are the top co-authors by number of shared publications:

  • Barbara Wilhelm

    University Eye Hospital, Centre for Ophthalmology, University Hospital Tübingen, Tübingen, Germany

    5 shared publications
  • Eberhart Zrenner

    University Eye Hospital, Centre for Ophthalmology, University Hospital Tübingen, Tübingen, Germany

    5 shared publications
  • Susanne Kohl

    Molecular Genetics Laboratory, Institute for Ophthalmic Research, Centre for Ophthalmology, University Hospital Tübingen, Tübingen, Germany

    5 shared publications
  • Marius Ueffing

    Institute for Ophthalmic Research, Centre for Ophthalmology, Centre for Ophthalmology, University Hospital Tubingen, Tübingen, Germany

    4 shared publications
  • Nicole Weisschuh

    Institute for Ophthalmic Research, Centre for Ophthalmology, Centre for Ophthalmology, University Hospital Tubingen, Tübingen, Germany

    4 shared publications
  • Ditta Zobor

    Institute for Ophthalmic Research, University of Tübingen, Tübingen, Baden-Württemberg, Germany

    3 shared publications

Latest Publications

  • Open Access

    Safety and vision outcomes of subretinal gene supplementation therapy in PDE6A -associated retinitis pigmentosa: a non-randomised controlled trial

    by Felix F Reichel, M Dominik Fischer, Katarina Stingl, Laura Kuehlewein, Immanuel Seitz, Tobias Peters, Melanie Ziegler, Barbara Wilhelm, Susanne Kohl, Nicole Weisschuh, et al.

    Purpose: PDE6A -associated retinitis pigmentosa (RP) is a rare inherited retinal disease leading to severe vision loss and blindness, with no available treatment. This study assessed the safety and vision outcomes of a gene therapy using an adeno-associated virus (AAV) vector encoding PDE6A (AAV8.hPDE6A). Methods: In an open-label, non-randomised controlled phase I/IIa trial, nine patients with biallelic PDE6A variants received a single subretinal injection of AAV8.hPDE6A. Doses were either 1.0×10¹⁰ (n=6) or 5.0×10¹⁰ (n=3) total vector genomes. Safety was the primary endpoint, assessed via clinical examinations, laboratory analyses and optical coherence tomography imaging. Secondary outcomes included changes in visual function, such as best corrected visual acuity (BCVA), contrast sensitivity, colour perception, dark adaptation thresholds, visual fields, patient-reported outcomes and chromatic pupil campimetry over 1 year. Results: The mean patient age was 40.1 years, with baseline BCVA ranging from 40 to 82 letters (0.9–0.1 logMAR). No systemic adverse events occurred, and most ocular events resolved without treatment. Persistent adverse events included small peripheral atrophic areas (n=2), disturbed colour discrimination (n=3), cataract (n=1), slight central retinal thinning (n=5) and moderate visual acuity loss (n=2, 1 in each dose group). BCVA, full-field stimulus thresholds and other visual function measures showed statistically non-significant changes, with a trend towards worsening of retinal sensitivity in the treated eyes. Conclusion: Subretinal gene therapy with AAV8.hPDE6A did not improve visual function over 1 year and posed risks, including central retinal thinning and visual acuity decline. This is in contrast to the safety and efficacy profile established in preclinical models.


  • Characterising the refractive error in paediatric patients with congenital stationary night blindness: a multicentre study

    by Austin D Igelman, Elizabeth White, Alaa Tayyib, Lesley Everett, Ajoy Vincent, Elise Heon, Christina Zeitz, Michel Michaelides, Omar A Mahroo, Mohamed Katta, et al.

    Background/Aaims: Congenital stationary night blindness (CSNB) is an inherited retinal disease that is often associated with high myopia and can be caused by pathological variants in multiple genes, most commonly CACNA1F , NYX and TRPM1 . High myopia is associated with retinal degeneration and increased risk for retinal detachment. Slowing the progression of myopia in patients with CSNB would likely be beneficial in reducing risk, but before interventions can be considered, it is important to understand the natural history of myopic progression. Methods: This multicentre, retrospective study explored CSNB caused by variants in CACNA1F , NYX or TRPM1 in patients who had at least 6 measurements of their spherical equivalent of refraction (SER) before the age of 18. A mixed-effect model was used to predict progression of SER overtime and differences between genotypes were evaluated. Results: 78 individuals were included in this study. All genotypes showed a significant myopic predicted SER at birth (−3.076D, −5.511D and −5.386D) for CACNA1F , NYX and TRPM1 respectively. Additionally, significant progression of myopia per year (−0.254D, −0.257D and −0.326D) was observed for all three genotypes CACNA1F , NYX and TRPM1 , respectively. Conclusions: Patients with CSNB tend to be myopic from an early age and progress to become more myopic with age. Patients may benefit from long-term myopia slowing treatment in the future and further studies are indicated. Additionally, CSNB should be considered in the differential diagnosis for early-onset myopia.


  • Open Access

    Biallelic Variants in TULP1 Are Associated with Heterogeneous Phenotypes of Retinal Dystrophy

    by Jan-Philipp Bodenbender, Valerio Marino, Leon Bethge, Katarina Stingl, Tobias B. Haack, Saskia Biskup, Susanne Kohl, Laura Kühlewein, Daniele Dell’orco, Nicole Weisschuh

    Biallelic pathogenic variants in TULP1 are mostly associated with severe rod-driven inherited retinal degeneration. In this study, we analyzed clinical heterogeneity in 17 patients and characterized the underlying biallelic variants in TULP1. All patients underwent thorough ophthalmological examinations. Minigene assays and structural analyses were performed to assess the consequences of splice variants and missense variants. Three patients were diagnosed with Leber congenital amaurosis, nine with early onset retinitis pigmentosa, two with retinitis pigmentosa with an onset in adulthood, one with cone dystrophy, and two with cone-rod dystrophy. Seventeen different alleles were identified, namely eight missense variants, six nonsense variants, one in-frame deletion variant, and two splice site variants. For the latter two, minigene assays revealed aberrant transcripts containing frameshifts and premature termination codons. Structural analysis and molecular modeling suggested different degrees of structural destabilization for the missense variants. In conclusion, we report the largest cohort of patients with TULP1-associated IRD published to date. Most of the patients exhibited rod-driven disease, yet a fraction of the patients exhibited cone-driven disease. Our data support the hypothesis that TULP1 variants do not fold properly and thus trigger unfolded protein response, resulting in photoreceptor death.


  • Three-year results of phase I retinal gene therapy trial for CNGA3-mutated achromatopsia: results of a non randomised controlled trial

    by Felix Friedrich Reichel, Stylianos Michalakis, Barbara Wilhelm, Ditta Zobor, Regine Muehlfriedel, Susanne Kohl, Nicole Weisschuh, Vithiyanjali Sothilingam, Laura Kuehlewein, Nadine Kahle, et al.

    Aims To determine long-term safety and efficacy outcomes of a subretinal gene therapy for CNGA3-associated achromatopsia. We present data from an open-label, nonrandomised controlled trial (NCT02610582). Methods Details of the study design have been previously described. Briefly, nine patients were treated in three escalating dose groups with subretinal AAV8.CNGA3 gene therapy between November 2015 and October 2016. After the first year, patients were seen on a yearly basis. Safety assessment constituted the primary endpoint. On a secondary level, multiple functional tests were carried out to determine efficacy of the therapy. Results No adverse or serious adverse events deemed related to the study drug occurred after year 1. Safety of the therapy, as the primary endpoint of this trial, can, therefore, be confirmed. The functional benefits that were noted in the treated eye at year 1 were persistent throughout the following visits at years 2 and 3. While functional improvement in the treated eye reached statistical significance for some secondary endpoints, for most endpoints, this was not the case when the treated eye was compared with the untreated fellow eye. Conclusion The results demonstrate a very good safety profile of the therapy even at the highest dose administered. The small sample size limits the statistical power of efficacy analyses. However, trial results inform on the most promising design and endpoints for future clinical trials. Such trials have to determine whether treatment of younger patients results in greater functional gains by avoiding amblyopia as a potential limiting factor.


  • Open Access

    Comparison of Methods for Estimating Retinal Shape: Peripheral Refraction vs. Optical Coherence Tomography

    by Katharina Breher, Alejandro Calabuig, Laura Kühlewein, Focke Ziemssen, Arne Ohlendorf, Siegfried Wahl

    Retinal shape presents a clinical parameter of interest for myopia, and has commonly been inferred indirectly from peripheral refraction (PRX) profiles. Distortion-corrected optical coherence tomography (OCT) scans offer a new and direct possibility for retinal shape estimation. The current study compared retinal curvatures derived from OCT scans vs. PRX measurements in three refractive profiles (0° and 90° meridians, plus spherical equivalent) for 25 participants via Bland–Altman analysis. The radial differences between both procedures were correlated to axial length using Pearson correlation. In general, PRX- and OCT-based retinal radii showed low correlation (all intraclass correlation coefficients < 0.21). PRX found flatter retinal curvatures compared to OCT, with the highest absolute agreement found with the 90° meridian (mean difference +0.08 mm) and lowest in the 0° meridian (mean difference +0.89 mm). Moreover, a negative relation between axial length and the agreement of both methods was detected especially in the 90° meridian (R = −0.38, p = 0.06). PRX measurements tend to underestimate the retinal radius with increasing myopia when compared to OCT measurements. Therefore, future conclusions from PRX on retinal shape should be made cautiously. Rather, faster and more clinically feasible OCT imaging should be performed for this purpose.


  • Open Access

    Genetic Spectrum of Syndromic and Non-Syndromic Hearing Loss in Pakistani Families

    by Julia Doll, Barbara Vona, Linda Schnapp, Franz Rüschendorf, Imran Khan, Saadullah Khan, Noor Muhammad, Sher Alam Khan, Hamed Nawaz, Ajmal Khan, et al.

    The current molecular genetic diagnostic rates for hereditary hearing loss (HL) vary considerably according to the population background. Pakistan and other countries with high rates of consanguineous marriages have served as a unique resource for studying rare and novel forms of recessive HL. A combined exome sequencing, bioinformatics analysis, and gene mapping approach for 21 consanguineous Pakistani families revealed 13 pathogenic or likely pathogenic variants in the genes GJB2, MYO7A, FGF3, CDC14A, SLITRK6, CDH23, and MYO15A, with an overall resolve rate of 61.9%. GJB2 and MYO7A were the most frequently involved genes in this cohort. All the identified variants were either homozygous or compound heterozygous, with two of them not previously described in the literature (15.4%). Overall, seven missense variants (53.8%), three nonsense variants (23.1%), two frameshift variants (15.4%), and one splice-site variant (7.7%) were observed. Syndromic HL was identified in five (23.8%) of the 21 families studied. This study reflects the extreme genetic heterogeneity observed in HL and expands the spectrum of variants in deafness-associated genes.


  • Open Access

    The perception threshold of the panda illusion, a particular form of 2D pulse-width-modulated halftone, correlates with visual acuity

    by Torsten Straßer, Anne Kurtenbach, Hana Langrová, Laura Kuehlewein, Eberhart Zrenner

    To call attention to the danger of extinction of the panda bear, the Lithuanian artist Ilja Klemencov created the artwork “They can disappear”. The illustration is composed of black-and-white zigzagged lines, which form the famous panda logo of the World Wild Fund For Nature (WWF) when seen from a distance. If one is too close to the artwork, it is difficult to spot the bear, however, if one steps back or takes off one’s glasses the panda suddenly appears. This led us to ask if the ability to see the panda is related to the visual acuity of the observer and if therefore, the panda illusion can be used to assess the spatial resolution of the eye. Here we present the results of the comparison between visual acuity determined using the Landolt C and that predicted from the panda illusion in 23 healthy volunteers with artificially reduced visual acuity. Furthermore, we demonstrate that the panda illusion is based on a 2D pulse-width modulation, explain its technical history, and provide the equations required to create the illusion. Finally, we explain why the illusion indeed can be used to predict visual acuity and discuss the neural causes of its perception with best-corrected visual acuity.


  • Open Access

    Genetic architecture of inherited retinal degeneration in Germany: A large cohort study from a single diagnostic center over a 9‐year period

    by Nicole Weisschuh, Carolin D. Obermaier, Florian Battke, Antje Bernd, Laura Kuehlewein, Fadi Nasser, Ditta Zobor, Eberhart Zrenner, Eva Weber, Bernd Wissinger, et al.

    We aimed to unravel the molecular genetic basis of inherited retinal degeneration (IRD) in a comprehensive cohort of patients diagnosed in the largest center for IRD in Germany. A cohort of 2,158 affected patients from 1,785 families diagnosed with IRD was analyzed by targeted next‐generation sequencing (NGS). Patients with single‐gene disorders (i.e., choroideremia and retinoschisis) were analyzed by Sanger sequencing and multiplex ligation‐dependent probe amplification. Our study cohort accounts for ∼7% of the estimated 30,000 patients with IRD in Germany, thereby providing representative data for both the prevalence of IRDs and the mutation spectrum of IRD genes for the population in Germany. We achieved a molecular diagnostic rate of 35–95%, depending on the clinical entities, with a high detection rate for achromatopsia, retinoschisis, and choroideremia, and a low detection rate for central areolar choroidal dystrophy and macular dystrophy. A total of 1,161 distinct variants were identified, including 501 novel variants, reaffirming the known vast genetic heterogeneity of IRD in a mainly outbred European population. This study demonstrates the clinical utility of panel‐based NGS in a large and highly heterogeneous cohort from an outbred population and for the first time gives a comprehensive representation of the genetic landscape of IRDs in Germany. The data are valuable and crucial for the scientific community and healthcare providers, but also for the pharmaceutical industry in the progressing field of personalized medicine and gene therapy.


  • Top Cited Papers

    Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia

    by M. Dominik Fischer, Stylianos Michalakis, Barbara Wilhelm, Ditta Zobor, Regine Muehlfriedel, Susanne Kohl, Nicole Weisschuh, G. Alex Ochakovski, Reinhild Klein, Christian Schoen, et al.

    Achromatopsia is an inherited disease that affects cone photoreceptors in the retina. Individuals with achromatopsia demonstrate a total lack of function of all 3 types of cones in the retina.1 Achromatopsia is clinically characterized by day blindness (hemeralopia), glare, poor visual acuity, involuntary oscillatory movement of the eyes (nystagmus), and failure to discriminate chromatic contrasts (achromatopsia). In contrast to common forms of color blindness, in which alterations in the opsin genes affect spectral sensitivity only, patients with achromatopsia lack any cone response from birth. Consequently, patients do not report progression of symptoms, and the disease was initially thought to be nonprogressive. Previous studies,2-4 however, established structural alterations and foveal lesions that emerge with age and are consistent with a slowly progressive degeneration and loss of cone photoreceptor cells in patients with achromatopsia. Variants in 6 genes are implicated in achromatopsia, which together likely explain more than 90% of cases.5,6 Most prevalent are pathogenic variants in the 2 genes that encode the α and β subunits of the cone cyclic nucleotide-gated (CNG) channel, CNGA3 (found in approximately 25%-28% of European and US cases) and CNGB3 (50% of cases).7 CNG channels are essential components of the phototransduction process in cone photoreceptors, which enable daylight vision, high spatial and temporal resolution, color discrimination, and stable fixation. No treatment is currently available for achromatopsia, and any procedure that results in improvement of day blindness and visual function is therefore desired.


  • Rebound Phenomenon after Intravitreal Injection of Triamcinolone Acetonide for Macular Edema

    by Ozlem Dikmetas, Laura Kuehlewein, Faik Gelisken

    Introduction: The aim of this article was to report on a rebound phenomenon after intravitreal triamcinolone acetonide (IVTA) injection for macular edema secondary to diabetic retinopathy (DR) and central or branch retinal vein occlusion (CRVO/BRVO). Methods: The data were analyzed retrospectively. Complete ophthalmic examinations, including spectral domain optical coherence tomography, were performed before and 2 months after IVTA injection. The incidence of a rebound phenomenon was defined as an increase in central retinal thickness of >10% from baseline at 2 months after IVTA injection. Results: This retrospective study included 211 consecutive patients (268 eyes). One hundred ninety (71.2%), 39 (14.6%), and 39 (14.6%) eyes had macular edema (ME) due to DR, CRVO, and BRVO. In total, 9.7% of the eyes showed a rebound phenomenon (DR: 9.5%, CRVO: 5.2%, BRVO: 15.4%). The mean number of prior injections of vascular endothelial growth factor inhibitor or corticosteroid agent was statistically significantly higher in the rebound group (6.8 vs. 5.3) than in the nonrebound group (p = 0.01). Conclusion: Our study shows that 9.7% of the eyes with ME secondary to DR and RVO developed a rebound phenomenon following IVTA injection, limiting its therapeutic effect. We found an increased number of prior intravitreal pharmacotherapy to be a risk factor for a rebound phenomenon.